Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

5,985 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
A single-arm Phase II validation study of preventing oxaliplatin-induced hypersensitivity reactions by dexamethasone: the AVOID trial.
Yoshida Y, Hirata K, Matsuoka H, Iwamoto S, Kotaka M, Fujita H, Aisu N, Hoshino S, Kosaka T, Maeda K, Kiyomi F, Yamashita Y. Yoshida Y, et al. Among authors: maeda k. Drug Des Devel Ther. 2015 Nov 11;9:6067-73. doi: 10.2147/DDDT.S94901. eCollection 2015. Drug Des Devel Ther. 2015. PMID: 26648694 Free PMC article. Clinical Trial.
[HAI chemotherapy for liver metastases of colorectal cancer].
Matsuoka H, Maeda K, Hanai T, Sato H, Masumori K, Koide Y, Katsuno H, Agata T, Noro T, Honda K, Shiota M, Ozeki S, Hatta K, Morise Z, Sugioka A, Ota H. Matsuoka H, et al. Among authors: maeda k. Gan To Kagaku Ryoho. 2010 Jul;37(7):1303-6. Gan To Kagaku Ryoho. 2010. PMID: 20647714 Japanese.
Phase II clinical study of modified FOLFOX7 (intermittent oxaliplatin administration) plus bevacizumab in patients with unresectable metastatic colorectal cancer-CRAFT study.
Tezuka T, Hamada C, Ishida H, Ooshiro M, Matsuoka H, Kawasaki S, Mishima H, Maeda K, Sakamoto J, Koda K. Tezuka T, et al. Among authors: maeda k. Invest New Drugs. 2013 Oct;31(5):1321-9. doi: 10.1007/s10637-013-9982-3. Epub 2013 Jul 2. Invest New Drugs. 2013. PMID: 23817973 Free PMC article. Clinical Trial.
High expression of organic anion transporter 2 and organic cation transporter 2 is an independent predictor of good outcomes in patients with metastatic colorectal cancer treated with FOLFOX-based chemotherapy.
Tashiro A, Tatsumi S, Takeda R, Naka A, Matsuoka H, Hashimoto Y, Hatta K, Maeda K, Kamoshida S. Tashiro A, et al. Among authors: maeda k. Am J Cancer Res. 2014 Sep 6;4(5):528-36. eCollection 2014. Am J Cancer Res. 2014. PMID: 25232494 Free PMC article.
Comparison between hypersensitivity reactions to cycles of modified FOLFOX6 and XELOX therapies in patients with colorectal cancer.
Ohta H, Hayashi T, Murai S, Shiouchi H, Ando Y, Kumazawa S, Ito K, Ikeda Y, Matsuoka H, Maeda K, Kawada K, Yasuda K, Yamada S. Ohta H, et al. Among authors: maeda k. Cancer Chemother Pharmacol. 2017 May;79(5):1021-1029. doi: 10.1007/s00280-017-3294-9. Epub 2017 Apr 8. Cancer Chemother Pharmacol. 2017. PMID: 28391355 Free PMC article.
5,985 results